217 related articles for article (PubMed ID: 34188177)
21. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53.
Wang W; Cheng JW; Qin JJ; Hu B; Li X; Nijampatnam B; Velu SE; Fan J; Yang XR; Zhang R
Cancer Lett; 2019 Sep; 459():156-167. PubMed ID: 31181320
[TBL] [Abstract][Full Text] [Related]
22. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
23. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation.
Zhang YY; Zhou LM
Biochem Biophys Res Commun; 2012 Jun; 423(1):26-31. PubMed ID: 22609775
[TBL] [Abstract][Full Text] [Related]
24. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
25. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.
Jung CR; Lim JH; Choi Y; Kim DG; Kang KJ; Noh SM; Im DS
J Clin Invest; 2010 Dec; 120(12):4493-506. PubMed ID: 21060154
[TBL] [Abstract][Full Text] [Related]
26. Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells.
Zhang YY; Zhou LM
Eur J Pharmacol; 2013 Jan; 698(1-3):137-44. PubMed ID: 23178529
[TBL] [Abstract][Full Text] [Related]
27. Differential SIRT1 expression in hepatocellular carcinomas and cholangiocarcinoma of the liver.
Al-Bahrani R; Tuertcher D; Zailaie S; Abuetabh Y; Nagamori S; Zetouni N; Bahitham W; Sergi C
Ann Clin Lab Sci; 2015; 45(1):3-9. PubMed ID: 25696003
[TBL] [Abstract][Full Text] [Related]
28. Flap endonuclease 1 Facilitated Hepatocellular Carcinoma Progression by Enhancing USP7/MDM2-mediated P53 Inactivation.
Bian S; Ni W; Zhu M; Zhang X; Qiang Y; Zhang J; Ni Z; Shen Y; Qiu S; Song Q; Xiao M; Zheng W
Int J Biol Sci; 2022; 18(3):1022-1038. PubMed ID: 35173534
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway.
Xu J; Xu S; Fang Y; Chen T; Xie X; Lu W
IUBMB Life; 2019 Mar; 71(3):347-356. PubMed ID: 30536701
[TBL] [Abstract][Full Text] [Related]
30. MiR-30e-3p Influences Tumor Phenotype through
Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
[TBL] [Abstract][Full Text] [Related]
31. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
[TBL] [Abstract][Full Text] [Related]
32. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma.
Koom WS; Park SY; Kim W; Kim M; Kim JS; Kim H; Choi IK; Yun CO; Seong J
J Radiat Res; 2012; 53(2):202-10. PubMed ID: 22510592
[TBL] [Abstract][Full Text] [Related]
33. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.
Zhang Q; Zeng SX; Zhang Y; Zhang Y; Ding D; Ye Q; Meroueh SO; Lu H
EMBO Mol Med; 2012 Apr; 4(4):298-312. PubMed ID: 22331558
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of SIRT1 in hepatocellular carcinoma.
Song S; Luo M; Song Y; Liu T; Zhang H; Xie Z
J Coll Physicians Surg Pak; 2014 Nov; 24(11):849-54. PubMed ID: 25404446
[TBL] [Abstract][Full Text] [Related]
35. CCAT2 contributes to hepatocellular carcinoma progression via inhibiting miR-145 maturation to induce MDM2 expression.
Niu C; Wang L; Ye W; Guo S; Bao X; Wang Y; Xia Z; Chen R; Liu C; Lin X; Huang X
J Cell Physiol; 2020 Sep; 235(9):6307-6320. PubMed ID: 32037568
[TBL] [Abstract][Full Text] [Related]
36. MiR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR.
Jiang D; Cho WC; Li Z; Xu X; Qu Y; Jiang Z; Guo L; Xu G
Biomed Pharmacother; 2017 Dec; 96():535-544. PubMed ID: 29032337
[TBL] [Abstract][Full Text] [Related]
37. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.
Simerzin A; Zorde-Khvalevsky E; Rivkin M; Adar R; Zucman-Rossi J; Couchy G; Roskams T; Govaere O; Oren M; Giladi H; Galun E
Hepatology; 2016 Nov; 64(5):1623-1636. PubMed ID: 27302319
[TBL] [Abstract][Full Text] [Related]
38. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
[TBL] [Abstract][Full Text] [Related]
39. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
Chen Y; Xin H; Peng H; Shi Q; Li M; Yu J; Tian Y; Han X; Chen X; Zheng Y; Li J; Yang Z; Yang L; Hu J; Huang X; Liu Z; Huang X; Zhou H; Cui X; Li F
Cancer Res; 2020 Jun; 80(11):2175-2189. PubMed ID: 32066565
[TBL] [Abstract][Full Text] [Related]
40. p53 Promotes proteasome-dependent degradation of oncogenic protein HBx by transcription of MDM2.
Xian L; Zhao J; Wang J; Fang Z; Peng B; Wang W; Ji X; Yu L
Mol Biol Rep; 2010 Jul; 37(6):2935-40. PubMed ID: 19842060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
